Kintor Competitors

Pink Sheets . USA . 
Stock . Kintor Pharmaceutical Limited
KNTPF Stock  USD 0.22  0.00  0.00%   
Kintor Pharmaceutical competes with Paradigm Biopharmaceutica, Nuo Therapeutics, Hofseth BioCare, Imugene, and Satellos Bioscience; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Kintor Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Kintor Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Kintor Pharmaceutical Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Kintor Pharmaceutical competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.010.222.57
Details
Intrinsic
Valuation
LowRealHigh
0.010.202.55
Details
Naive
Forecast
LowNextHigh
00.242.59
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.210.260.30
Details

Kintor Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Kintor Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Kintor and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Kintor Pharmaceutical does not affect the price movement of the other competitor.

High positive correlations

HOFBF
+ 1.0
POLBF
MSCLF
+ 0.54
IUGNF
MSCLF
+ 0.51
AURX
IUGNF
+ 0.48
PBIGF
AURX
+ 0.36
PBIGF
MSCLF
+ 0.34
PBIGF
  

High negative correlations

SCNLF
- 0.39
MSCLF
SCNLF
- 0.36
PBIGF
SCNLF
- 0.22
AURX
SCNLF
- 0.18
IUGNF
SHIEF
- 0.12
SCNLF
IPHYF
- 0.09
MSCLF

Risk-Adjusted Indicators

There is a big difference between Kintor Pink Sheet performing well and Kintor Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kintor Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PBIGF  4.88  0.84  0.05 (0.51) 5.49 
(13.13)
 16.67 
(13.33)
 60.62 
POLBF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
AURX  4.24  0.52  0.06 (2.87) 5.05 
(7.17)
 7.98 
(7.79)
 59.68 
HOFBF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
IUGNF  5.96  0.54  0.07  0.53  5.36 
(10.98)
 20.00 
(9.09)
 41.90 
MSCLF  2.72  0.00 (0.02) 0.02  3.26 
(3.75)
 7.55 
(5.77)
 18.87 
SCNLF  0.50  0.10  0.00  0.40  0.00 
 0.00 
 0.00 
 0.00 
 16.67 
SHIEF  2.28  0.46  0.00  0.24  0.00 
 0.00 
 0.00 
 0.00 
 61.79 
VSBC  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
IPHYF  0.38  0.14  0.00 (0.33) 0.00 
 0.00 
 0.00 
 0.00 
 12.57 
All Fundamental Data

Kintor Pharmaceutical Competitive Analysis

The better you understand Kintor Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Kintor Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Kintor Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
KNTPF PBIGF POLBF AURX HOFBF IUGNF MSCLF SCNLF SHIEF VSBC
 0.00 
 0.22 
Kintor
 0.00 
 0.23 
Paradigm
 0.00 
 0.04 
Poolbeg
 7.50 
 2.15 
Nuo
 0.00 
 0.17 
Hofseth
 4.55 
 0.23 
Imugene
 4.00 
 0.48 
Satellos
 0.00 
 0.14 
Scancell
 44.28 
 0.13 
Shield
 0.00 
 1.00 
VitaSpring
Market Volatility
(90 Days Market Risk)
Out of control
Out of control
Very steady
Dangerous
Very steady
Out of control
Abnormally volatile
Out of control
Out of control
Very steady
Market Performance
(90 Days Performance)
Weakest
Mild
Weakest
Soft
Weakest
Mild
Weakest
Soft
Mild
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Average
High
High
Low
Fair
High
High
Low
Moderate
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Current Ratio
3.44
6.02
48.98
8.33
0.92
15.32
1.04
24.05
2.6
4.23
Net Asset
2.07 B
50.69 M
N/A
149.93 K
415.97 M
147.61 M
12.59 M
38.52 M
44.41 M
3.6 M
Profit Margin
N/A
N/A
N/A
N/A
-1.14
-2.92
N/A
-1.6
N/A
0.19
EBITDA
(833.82 M)
(39.16 M)
(3.24 M)
(90.67 K)
(87.72 M)
(37.56 M)
(4.49 M)
(146 K)
(17.35 M)
1.49 M
Operating Margin
-30.26
-604.99
N/A
-63.5
-1.07
-2.91
N/A
-2.06
-7.83
0.24
Current Valuation
692.39 M
217 M
N/A
61.85 M
103.14 M
737.79 M
7.17 M
239.16 M
18.31 M
2.89 B
Price To Book
5.15
8.76
N/A
20.43
16.71
8.51
1.1
5.89
0.75
1621.51
Beta
-0.19
1.12
N/A
-434.9
0.54
2.06
N/A
0.48
1.1
1.43
Number Of Employees
328
16
7
4
17
17
7
40
15
3
Shares Outstanding
447.5 M
282.24 M
500 M
41.8 M
395.08 M
6.42 B
41.8 M
818.4 M
585.67 M
206.52 M
Cash Flow From Operations
(1.05 B)
(32.21 M)
(2.86 M)
(119.95 K)
(61.78 M)
(30.85 M)
(5.03 M)
(10.19 M)
(16.74 M)
84.81 K
Total Debt
147.5 M
616.67 K
N/A
352.88 K
23.79 M
673.43 K
N/A
7.01 M
156 K
375.5 K
Return On Equity
-0.62
-0.65
N/A
-1.74
-0.95
-0.37
-0.86
-0.44
-0.57
0.84
Z Score
2.4
N/A
N/A
N/A
3.0
N/A
N/A
37.2
N/A
N/A
Return On Asset
-0.31
-0.44
N/A
-0.76
-0.19
-0.21
-0.4
-0.16
-0.34
0.41
Book Value Per Share
3.06
0.18
0.042
0.075
0.39
0.024
0.2
0.019
0.15
0.008
Total Asset
2.07 B
50.69 M
N/A
149.93 K
415.97 M
147.61 M
12.59 M
38.52 M
44.41 M
3.6 M
Debt To Equity
0.2
0.014
N/A
0.099
1.25
0.004
N/A
0.35
0.003
0.21
Shares Owned By Institutions
8.41
18.7
6.95
6.47
20.43
8.67
14.41
49.22
13.58
N/A
Market Capitalization
626.5 M
347.15 M
60.65 M
62.18 M
130.38 M
642.17 M
15.29 M
435.14 M
51.48 M
3.1 B
Price To Earning
N/A
N/A
N/A
0.63
N/A
N/A
N/A
-8.0
N/A
N/A
Price To Sales
17.86
3287.04
N/A
1682.89
1.21
61.84
295.34
N/A
7.37
558.27
Net Income
(842.1 M)
(39.25 M)
(3.11 M)
(90.67 K)
(126.46 M)
(37.87 M)
(15.51 M)
(2.06 M)
(19.34 M)
1.26 M
Earnings Per Share
-0.35
-0.14
N/A
-0.04
-0.038
-0.004
-0.46
-0.013
-0.11
N/A
Shares Owned By Insiders
31.95
16.46
19.57
54.88
52.5
15.4
9.3
6.63
42.23
58.7
Revenue
34.23 M
79.22 K
N/A
N/A
87.62 M
12.97 M
N/A
N/A
1.52 M
5.61 M
Cash And Equivalents
387.49 M
39.72 M
18.89 M
3.44 M
30.57 M
99.89 M
1.93 M
35.57 M
2.4 M
21.59 K
Cash Per Share
1.0
0.17
0.04
0.08
0.09
0.02
0.06
0.04
0.01
N/A
Gross Profit
34.23 M
(64.53 K)
N/A
1.21 M
28.51 M
12.97 M
(793.97 K)
N/A
539 K
2.06 M
Day Typical Price
0.22
0.23
0.0425
2.15
0.17
0.23
0.48
0.14
0.13
1.0
Accumulation Distribution
N/A
N/A
N/A
N/A
N/A
N/A
0.0204
N/A
N/A
N/A
Market Facilitation Index
N/A
N/A
N/A
N/A
N/A
N/A
0.01
N/A
N/A
N/A
Daily Balance Of Power
0.0
0.0
0.0
9.2 T
0.0
9.2 T
(2.00)
0.0
9.2 T
0.0
Period Momentum Indicator
N/A
N/A
N/A
0.15
N/A
0.01
(0.02)
N/A
0.0399
N/A
Rate Of Daily Change
1.0
1.0
1.0
1.08
1.0
1.05
0.96
1.0
1.44
1.0
Day Median Price
0.22
0.23
0.0425
2.15
0.17
0.23
0.49
0.14
0.13
1.0
Price Action Indicator
N/A
N/A
N/A
0.075
N/A
0.005
(0.01)
N/A
0.02
N/A
Coefficient Of Variation
(1,050)
1215.97
N/A
1399.3
N/A
1363.47
43853.44
1671.39
1163.61
N/A
Mean Deviation
0.5544
4.88
N/A
4.24
N/A
5.96
2.72
0.5009
2.28
N/A
Jensen Alpha
(0.24)
0.8443
N/A
0.5172
N/A
0.5355
0.0041
0.1037
0.4584
N/A
Total Risk Alpha
(0.47)
(0.17)
N/A
(0.21)
N/A
(0.24)
(0.38)
(0.10)
(0.12)
N/A
Sortino Ratio
N/A
0.0531
N/A
0.0595
N/A
0.0714
(0.02)
N/A
N/A
N/A
Downside Variance
N/A
160.49
N/A
53.3
N/A
58.73
18.96
N/A
N/A
N/A
Standard Deviation
2.34
9.15
N/A
7.2
N/A
8.55
3.79
2.27
7.7
N/A
Kurtosis
60.59
7.25
N/A
9.55
N/A
2.23
0.6263
46.46
23.0
N/A
Potential Upside
N/A
16.67
N/A
7.98
N/A
20.0
7.55
N/A
N/A
N/A
Treynor Ratio
(2.50)
(0.51)
N/A
(2.87)
N/A
0.5306
0.0174
0.3976
0.2368
N/A
Maximum Drawdown
22.36
60.62
N/A
59.68
N/A
41.9
18.87
16.67
61.79
N/A
Variance
5.45
83.78
N/A
51.91
N/A
73.13
14.39
5.17
59.3
N/A
Market Risk Adjusted Performance
(2.49)
(0.50)
N/A
(2.86)
N/A
0.5406
0.0274
0.4076
0.2468
N/A
Risk Adjusted Performance
(0.06)
0.0671
N/A
0.0593
N/A
0.0608
0.0097
0.049
0.0696
N/A
Skewness
(7.55)
1.71
N/A
1.31
N/A
1.29
0.2876
5.46
3.02
N/A
Semi Deviation
N/A
5.49
N/A
5.05
N/A
5.36
3.26
N/A
N/A
N/A
Information Ratio
(0.13)
0.0735
N/A
0.0603
N/A
0.064
(0.02)
0.0245
0.0755
N/A
Value At Risk
N/A
(13.33)
N/A
(7.79)
N/A
(9.09)
(5.77)
N/A
N/A
N/A
Expected Short fall
N/A
(13.13)
N/A
(7.17)
N/A
(10.98)
(3.75)
N/A
N/A
N/A
Downside Deviation
N/A
12.67
N/A
7.3
N/A
7.66
4.35
N/A
N/A
N/A
Semi Variance
N/A
30.1
N/A
25.54
N/A
28.72
10.63
N/A
N/A
N/A

Kintor Pharmaceutical Competition Performance Charts

Five steps to successful analysis of Kintor Pharmaceutical Competition

Kintor Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Kintor Pharmaceutical in relation to its competition. Kintor Pharmaceutical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Kintor Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Kintor Pharmaceutical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Kintor Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Kintor Pharmaceutical position

In addition to having Kintor Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Compulsion Thematic Idea Now

Compulsion
Compulsion Theme
Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. The Compulsion theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Compulsion Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Kintor Pink Sheet

Kintor Pharmaceutical financial ratios help investors to determine whether Kintor Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kintor with respect to the benefits of owning Kintor Pharmaceutical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY